Genmab A/S

Company Profile

Genmab A/S had its IPO on under the ticker symbol GNMSF.

The company operates in the Healthcare sector and Biotechnology industry. Genmab A/S has a staff strength of 2,015 employees.

Stock update

Shares of Genmab A/S opened at $366.8 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $360 - $372.4, and closed at $366.1.

This is a -0.78% slip from the previous day's closing price.

A total volume of 136 shares were traded at the close of the day’s session.

In the last one week, shares of Genmab A/S have slipped by -4.77%.

Genmab A/S's Key Ratios

Genmab A/S has a market cap of $24.09 billion, indicating a price to book ratio of 7.9422 and a price to sales ratio of 2.4516.

In the last 12-months Genmab A/S’s revenue was $16.37 billion with a gross profit of $14.60 billion and an EBITDA of $6.93 billion. The EBITDA ratio measures Genmab A/S's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Genmab A/S’s operating margin was 40.13% while its return on assets stood at 13.81% with a return of equity of 17.84%.

In Q2, Genmab A/S’s quarterly earnings growth was a negative -28.1% while revenue growth was a positive 32.8%.

Genmab A/S’s PE and PEG Ratio

Forward PE

35.0877

Trailing PE

35.1405

PEG

1.2001

Its diluted EPS in the last 12-months stands at $10.5 per share while it has a forward price to earnings multiple of 35.0877 and a PEG multiple of 1.2001. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Genmab A/S’s profitability.

Genmab A/S stock is trading at a EV to sales ratio of 2.2031 and a EV to EBITDA ratio of 3.5891. Its price to sales ratio in the trailing 12-months stood at 2.4516.

Genmab A/S stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$31.98 billion

Total Liabilities

$1.99 billion

Operating Cash Flow

$0

Capital Expenditure

$107 million

Dividend Payout Ratio

0%

Genmab A/S ended 2024 with $31.98 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $31.98 billion while shareholder equity stood at $28.76 billion.

Genmab A/S ended 2024 with $0 in deferred long-term liabilities, $1.99 billion in other current liabilities, 66000000.00 in common stock, $16.17 billion in retained earnings and $0 in goodwill. Its cash balance stood at $10.87 billion and cash and short-term investments were $24.88 billion. The company’s total short-term debt was $82,000,000 while long-term debt stood at $0.

Genmab A/S’s total current assets stands at $29.75 billion while long-term investments were $183.00 million and short-term investments were $14.01 billion. Its net receivables were $4.81 billion compared to accounts payable of $0 and inventory worth $51.00 million.

In 2024, Genmab A/S's operating cash flow was $0 while its capital expenditure stood at $107 million.

Comparatively, Genmab A/S paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$366.1

52-Week High

$470.5

52-Week Low

$303.41

Analyst Target Price

$

Genmab A/S stock is currently trading at $366.1 per share. It touched a 52-week high of $470.5 and a 52-week low of $470.5. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $384.07 and 200-day moving average was $395.92 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 4998.3% are held by institutions.